Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIVA-TAK
NCT07451665Phase 4Not yet recruiting
- Sponsor
- Chinese SLE Treatment And Research Group
- Start
- Apr 2026
- Primary completion
- Mar 2029
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of vunakizumab, ivarmacitinib in Takayasu's arteritis (TAK), sponsored by Chinese SLE Treatment And Research Group. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
vunakizumabivarmacitinib
03
Conditions
Takayasu's arteritis (TAK)
Beyond the preview
Go deeper on NCT07451665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07451665.